AGM/EGMApr 30, 2026, 04:43 PM
ALLO to double authorized shares to 800M; Board size reduced
AI Summary
Allogene Therapeutics will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026. Key proposals include the election of three directors, advisory votes on executive compensation and its frequency, and a proposal to increase authorized common stock from 400 million to 800 million shares. The Board of Directors will also be reduced from eleven to ten members, with Mr. Todd Sisitsky not standing for re-election. The company highlighted 2025 progress in its cema-cel, ALLO-316, and ALLO-329 programs, alongside operational and cost realignment initiatives.
Key Highlights
- Proposal to increase authorized common stock from 400,000,000 to 800,000,000 shares.
- 2026 Annual Meeting of Stockholders scheduled for June 18, 2026.
- Board of Directors to be reduced from 11 to 10 members.
- Three directors nominated for election to serve until the 2029 Annual Meeting.
- Advisory vote on executive compensation and its preferred frequency (Board recommends 1 year).
- Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026.
- ALLO-316 Phase 1 TRAVERSE data showed 31% confirmed response rate.
- ALLO-329 autoimmune program received 3 FDA Fast Track designations.
Price Impact
More from ALLO